Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

First Posted Date
2024-12-17
Last Posted Date
2024-12-17
Lead Sponsor
University of Washington
Target Recruit Count
30
Registration Number
NCT06738368
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

First Posted Date
2024-12-13
Last Posted Date
2024-12-13
Lead Sponsor
Sichuan University
Target Recruit Count
12
Registration Number
NCT06732258

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

First Posted Date
2024-12-06
Last Posted Date
2024-12-06
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Target Recruit Count
54
Registration Number
NCT06719973
Locations
🇺🇸

Please Contact U.S. Medical Information, Billerica, Massachusetts, United States

🇩🇪

Please Contact the Communication Center, Darmstadt, Germany

Safety and Effectiveness of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

First Posted Date
2024-12-02
Last Posted Date
2024-12-02
Lead Sponsor
BioNTech SE
Target Recruit Count
439
Registration Number
NCT06712355

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

First Posted Date
2024-11-18
Last Posted Date
2024-11-18
Lead Sponsor
Eric Jacobsen, MD
Target Recruit Count
24
Registration Number
NCT06692452
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

First Posted Date
2024-11-11
Last Posted Date
2024-11-11
Lead Sponsor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Target Recruit Count
380
Registration Number
NCT06682611

Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

First Posted Date
2024-10-29
Last Posted Date
2024-10-29
Lead Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Target Recruit Count
142
Registration Number
NCT06663098
Locations
🇮🇹

Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy

🇮🇹

IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy

🇮🇹

IRCCS Azienda Ospedaliero_Universitaria di Bologna, Bologna, Italy

and more 22 locations

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

First Posted Date
2024-10-18
Last Posted Date
2024-10-18
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Target Recruit Count
100
Registration Number
NCT06648200
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, China

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

First Posted Date
2024-10-17
Last Posted Date
2024-12-20
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
530
Registration Number
NCT06646276
Locations
🇨🇳

Local Institution - 0335, Xi'an, Shaanxi, China

🇺🇸

Local Institution - 0245, Fort Myers, Florida, United States

🇺🇸

Local Institution - 0009, Orange City, Florida, United States

and more 150 locations

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

First Posted Date
2024-08-21
Last Posted Date
2024-12-16
Lead Sponsor
AstraZeneca
Target Recruit Count
660
Registration Number
NCT06564844
Locations
🇻🇳

Research Site, Vinh, Vietnam

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy